NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

Here are six DC therapy trials conducted by Mayo. Should the longs get excited in the thought these trials must be related to our Coca-Cola formula type of technology? Or should the longs psychologically be prepared for the fact that there is a silent and formidable competitor that can push $NWBO to the verge of bankruptcy? Clearly, Merck has close connection with those researchers at Mayo Clinic. Why did Merck not go ahead to acquire everything developed by Mayo? Why did Merck replace BMS as the new collaborator in the new SPORE project? Seems to me that Merck doesn't need to get involved in the combo trial.

Question: All these trials were conducted many years ago. Were these trials discussed before on this board?

Vaccine Therapy in Treating Patients With Recurrent Glioblastoma
https://clinicaltrials.gov/study/NCT03360708
Sponsor Mayo Clinic
Study Start (Actual): 2013-11-27
Primary Completion (Actual): 2021-06-02
Principal Investigator: Ian Parney,Mayo Clinic

Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
https://clinicaltrials.gov/study/NCT01957956
Study Start (Actual): 2013-11-11
Primary Completion (Actual): 2016-11-16
Principal Investigator: Ian Parney,Mayo Clinic

https://openpaymentsdata.cms.gov/payment/2022/research/940392617
https://openpaymentsdata.cms.gov/payment/2021/research/848759061

Novel strategy for manufacturing autologous dendritic cell/allogeneic tumor lysate vaccines for glioblastoma
https://academic.oup.com/noa/article/2/1/vdaa105/5897132

Phase I trial of adjuvant mature autologous dendritic cell/allogeneic tumor lysate vaccines in combination with temozolomide in newly diagnosed glioblastoma
https://academic.oup.com/noa/article/4/1/vdac089/6617567

Mill Creek Life Sciences
https://millcreekls.com/dendritic-cell-vaccine-2/

In total, 10/20 evaluable patients had subsequent tissue diagnosis at imaging progression after receiving vaccine. Of these, 5 (50%) had viable recurrent tumor without significant inflammation or treatment-related changes. Four (40%) had a mixture of viable recurrent/residual tumor and inflammation but were interpreted as predominantly tumor. These patients were taken off treatment. One patient had predominantly treatment-related inflammation and necrosis and subsequently resumed study treatment. In all 5 patients with significant inflammatory cell infiltrates, this was predominantly represented by CD3+ or CD4+T cells as well as CD68+ or CD163+ macrophages with smaller contributions from CD8+ T cells and scant or absent CD20+ B cells. Representative imaging, histological, and immunohistochemical findings at imaging recurrence are shown in Figure 2B and C.

Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma
https://clinicaltrials.gov/study/NCT03325101
Sponsor Mayo Clinic
Study Start (Actual): 2017-11-15
Primary Completion (Actual): 2020-06-14
Principal Investigator:Matthew S. Block, M.D., Ph.D.,Mayo Clinic

https://openpaymentsdata.cms.gov/payment/2024/research/1136442181

Phase Ib/II Study of Autologous Dendritic Cell Therapy Delivered Intratumorally After Cryoablation in Combination With Pembrolizumab for Patients With Metastatic or Unresectable Melanoma
https://cdn.clinicaltrials.gov/large-docs/01/NCT03325101/Prot_SAP_000.pdf



Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
https://clinicaltrials.gov/study/NCT02111941
Study Start (Actual): 2014-04-14
Primary Completion (Actual): 2021-07-27
Principal Investigator:Matthew S. Block, M.D., Ph.D.,Mayo Clinic

Abstract TMEM-016: DENDRITIC CELL VACCINATION AND INHIBITION OF TUMOR–ASSOCIATED IMMUNE SUPPRESSION
https://aacrjournals.org/clincancerres/article/23/11_Supplement/TMEM-016/12562/Abstract-TMEM-016-DENDRITIC-CELL-VACCINATION-AND

Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients
https://www.nature.com/articles/s41467-020-18962-z

https://newsnetwork.mayoclinic.org/discussion/harnessing-the-immune-system-to-fight-ovarian-cancer/

"We're building on an earlier phase 1 clinical trial that showed promising results in terms of survival after the dendritic cell-based vaccine," says Matthew Block, M.D., Ph.D., co-principal investigator and medical oncologist. "Of the 18 evaluable patients in the phase 1 study, 11 had cancer return, but seven of them — 40 % — have been cancer-free for almost 10 years. We typically expect 90% of patients in this condition to have the cancer return."

Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma
https://clinicaltrials.gov/study/NCT01239875
Study Start (Actual): 2010-11
Primary Completion (Actual): 2015-11-24
Study Chair:Yi Lin, M.D.,Mayo Clinic

Patient must have at least 2 measurable lesions that are >= 1.5cm in one dimension. One of the lesions, must meet additional criteria a or b depending on the treatment arm.

a) For Arm A, patient must have at least one lesion that is >= 2.0cm and is amenable to image-guided cryoablation and multiple vaccine injections as determined by Interventional Radiology (including tumors that can be safely accessed using imaging guidance and treated with minimal risk to adjacent structures).

b) For Arm B, patient must have one lesion that can be excised for in vitro vaccine preparation.

Dendritic cell vaccine treatment for indolent B cell non-hodgkin lymphoma: clinical trial in progress
https://www.sciencedirect.com/science/article/pii/S0006497119733825





Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma
Phase I/II Study of Dendritic Cell Therapy Delivered Intratumorally After Cryoablation and Anti-PD-1 Antibody (Pembrolizumab) for Patients With Non-Hodgkin Lymphoma
https://clinicaltrials.gov/study/NCT03035331
Study Start (Actual): 2017-08-15
Primary Completion (Actual): 2022-01-25
Principal Investigator:Yi Lin, MD, PhD,Mayo Clinic

https://openpaymentsdata.cms.gov/payment/2018/research/607019675